Lucid Diagnostics Inc expected to post a loss of 19 cents a share - Earnings Preview

Lucid Diagnostics

21/03/2025 12:37

Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to show a rise in quarterly revenue when it reports  results on March 24 for the period ending December 31 2024

The New York City-based  company is expected to report a 36.7% increase in revenue to $1.422 million from $1.04 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lucid Diagnostics Inc is for a loss of 19 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00​, above​ its last closing price of $1.57. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.22
-0.22
-0.25
Missed
-13.6
Jun. 30 2024
-0.22
-0.22
-0.23
Missed
-4.5
Mar. 31 2024
-0.26
-0.27
-0.40
Missed
-49.3​
Dec. 31 2023
-0.27
-0.26
-0.25
Beat
3
​​Sep. 30 2023
-0.27
-0.27
-0.34
Missed
-24.8
Jun. 30 2023
-0.32
-0.32
-0.23
Beat
28.3​
Mar. 31 2023
-0.34
-0.35
-0.40
Missed
-14.7
Dec. 31 2022
-0.37
-0.38
-0.23
Beat
39.3

This summary was machine generated March 21 at 12:37 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)